论文部分内容阅读
研制开发更好的结核病疫苗的研究现在正处于重要的转折点。在过去的十余年中,由实验室模型得到的备选疫苗如改良卡介苗、减毒结核杆菌疫苗、蛋白质或DNA亚单位疫苗现在正在准备进行临床试验。它们从实验室走向临床试验具有广泛的战略和技术意义。需要确认生产临床疫苗所需的设施和资金,一个难题是有些备选疫苗含有活菌;需要克服 常规困难;制订试验规程,选择试验地点,Ⅲ期临床实验尤其如此。遏制结核病工作组结核疫苗发展中心组织了一个全球论坛,组织实验室和临床研究人员及结核病控制专家、商业代表、非赢利性基金机构一起讨论这些问题,加快实现共同目标-改进结核病疫苗策略。
Research into developing better TB vaccines is now at an important turning point. Over the past decade, alternative vaccines such as modified BCG, attenuated M. tuberculosis vaccine, protein or DNA subunit vaccines obtained from laboratory models are now undergoing clinical trials. They have a wide range of strategic and technical implications from the lab to clinical trials. One challenge is the need to identify the facilities and funding needed to produce clinical vaccines. One challenge is that some alternative vaccines contain viable bacteria; routine difficulties need to be overcome; test protocols are set and test sites are chosen, especially in phase III clinical trials. The TB Stop TB Vaccine Development Center has organized a global forum to organize laboratory and clinical researchers and TB control experts, business representatives and non-profit fund agencies to discuss these issues together to accelerate the common goal of improving tuberculosis vaccine strategies.